A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
NCT ID: NCT06057935
Last Updated: 2025-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
64 participants
INTERVENTIONAL
2023-09-21
2028-09-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
NCT00024271
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NCT04158141
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
NCT01874119
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
NCT06207305
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
NCT00007995
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IVC arm
Pemetrexed and cisplatin will be administered intravenously for a total of 4 to 6 cycles. Participants will receive 4 cycles, but can receive up to 6 cycles based on clinician discretion. Substitution with carboplatin allowed for pre-existing impairment of hearing, renal function, or neuropathy.
Pemetrexed
Pemetrexed will be administered intravenously
Cisplatin
Cisplatin will be administered intravenously
Carboplatin
Possible substitution with carboplatin based on clinician discretion
NIPC arm
After completion of hyperthermic intraperitoneal chemotherapy/HIPEC, an intraperitoneal catheter with a subcutaneous reservoir will be inserted through the abdominal wall. When the participant's condition is considered stable by the physicians, the NIPC will be started. Pemetrexed and either cisplatin or carboplatin will be administered through the intraperitoneal port.
Pemetrexed
Pemetrexed will be administered intravenously
Cisplatin
Cisplatin will be administered intravenously
Carboplatin
Possible substitution with carboplatin based on clinician discretion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pemetrexed
Pemetrexed will be administered intravenously
Cisplatin
Cisplatin will be administered intravenously
Carboplatin
Possible substitution with carboplatin based on clinician discretion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of MPM at enrolling institution.
* Prior to randomization, intraoperative pathologic confirmation of epithelioid MPM at enrolling institution.
* Complete or near-complete CRS achieved.
* Patient must be planning to undergo complete cytoreduction of all peritoneal disease.
* ECOG performance status ≤ 1.
* Hematology: ANC ≥ 1,500/µl.
* Platelets \> 75,000/µl.
* Adequate renal function: creatinine \< 1.5× the upper limit of normal (ULN) or calculated creatinine clearance of ≥50 ml/min.
* Adequate hepatic function: bilirubin \< 1.5 mg/dl (except in patients with Gilbert's syndrome, who must have total bilirubin \< 3.0 mg/dL).
* Women of childbearing potential with a negative pregnancy test result (urine or blood) who agree to use an effective contraceptive method. Reliable contraception should be used from trial screening and must be continued throughout the study. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant.
* A man participating in this study must agree to utilize a reliable barrier form of contraception for the duration of the study
* Signed and dated written informed consent to participate in this clinical trial must be obtained prior to any study procedure.
Exclusion Criteria
* Subjects who have previously received platinum-containing chemotherapy regimens.
* Subjects with preoperative or intraoperative biopsy consistent with sarcomatoid mesothelioma, well-differentiated papillary mesothelioma, or benign multicystic mesothelioma.
* Other prior malignancies, except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, adequately treated malignancies for which there has been no evidence of activity for more than three years, or indolent tumors for which observation over two years is a reasonable option.
* High suspicion for extra-abdominal metastases.
* Women who are pregnant or lactating.
* Active coronary artery disease (defined as unstable angina or a positive cardiac stress test). Subjects with a history of coronary artery disease may be included if they have had a normal stress test within 60 days of enrollment or are determined by a cardiologist to be of acceptable perioperative risk.
* Uncontrolled hypertension defined as \>140/90 and not cleared for surgery at the time of consent.
* New York Heart Association (NYHA) Class II or higher congestive heart failure; restrictive or obstructive pulmonary disease that would limit study compliance or place the patient at unacceptable risk for participation in the study.
* History of cerebrovascular disease that would limit study compliance or place the patient at unacceptable risk for participation in the study.
* Subjects with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or place them at an unacceptable risk for participation in the study.
* Patients with known cisplatin, carboplatin, pemetrexed or mitomycin allergy.
* Evidence of extensive intraperitoneal adhesions at the time of surgery which prohibits intraperitoneal therapy, as determined by the operating surgeon.
* Any condition that would preclude the ability to deliver appropriate IP therapy.
* Use of an oral medication, lacking a suitable non-oral substitute, that if held for up to ten days, would be felt an unacceptable risk by the investigator.
* Life expectancy \< 12 weeks.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Garrett Nash, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago (Data Collection Only)
Chicago, Illinois, United States
University of Michigan (Data Collection Only)
Ann Arbor, Michigan, United States
Washington University (Data Collection Only)
St Louis, Missouri, United States
University of Nebraska (Data collection only)
Omaha, Nebraska, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States
Rutgers University (Data Collection Only)
New Brunswick, New Jersey, United States
Memorial Sloan Kettering Commack (Limited Protocol Activities)
Commack, New York, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activites)
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, United States
Allegheny Health Network (Data Collection Only)
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hedy Kindler, MD
Role: primary
Donnele Daley, MD
Role: primary
Trang Nguyen, MD
Role: primary
Jason Foster, MD
Role: primary
Garrett Nash, MD, MPH
Role: primary
Garrett Nash, MD
Role: primary
Garrett Nash, MD
Role: primary
H. Richard Alexander, MD
Role: primary
Garrett Nash, MD
Role: primary
Garrett Nash, MD
Role: primary
Garrett Nash, MD
Role: primary
Garrett Nash, MD
Role: primary
Patrick Wagner, MD
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-145
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.